Is it better to take Eltrombopag/Eltrombopag or Haiqu for patients with aplastic anemia?

Aplastic anemia is currently treated with immunosuppressive therapy (IST) using antithymocyte globulin and cyclosporine, to which two-thirds of patients respond. However, a large proportion of these responders relapse, and many have persistent cytopenias. A trial shows that Eltrombopag is effective in treating patients with severe aplastic anemia (SAA) refractory to IST. There is evidence that this drug works by directly stimulating bone marrow stem and progenitor cells, thereby promoting hematopoietic recovery in patients with bone marrow failure.

Eltrombopag is a synthetic, non-peptideTPO mimetic that can be administered orally. It was originally used to treat chronic immune thrombocytopenia. Eltrombopag selectively binds to C-mpl in the transmembrane region and juxtamembrane region of the thrombopoietin receptor, and the binding site is different from the binding site of TPO. Eltrombopag therefore does not compete with the natural molecule for binding. Hetrombopag is also a thrombopoietin receptor agonist and can be used to treat thrombocytopenia, including immune thrombocytopenia and aplastic anemia. The mechanisms of action of eltrombopag and eltrombopag are similar. They both promote the proliferation and differentiation of platelet precursor cells in the bone marrow by simulating the effects of thrombopoietin in the body, thereby increasing the number of platelets.xa0

Therefore, for patients with aplastic anemia, the choice of eltrombopag/eltrombopag or haitrimida should be decided based on the specific situation and the doctor's advice. If the patient's condition is more severe and requires a rapid increase in platelet count, then eltrombopag may be a better choice. If the patient's disease is mild, or if there is an intolerance or allergic reaction to eltrombopag, eltrombopag may be a suitable option. No matter which drug is chosen, it needs to be carried out under the guidance of a doctor to ensure the safety and effectiveness of the treatment.